Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

NCT01862081 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01862081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01862081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 16, 2013
Completion date
June 9, 2017
Enrollment
80 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non-small lung cancer